Federated Hermes Inc. Buys 12,118 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Federated Hermes Inc. lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 192,165 shares of the biotechnology company’s stock after acquiring an additional 12,118 shares during the quarter. Federated Hermes Inc. owned about 0.06% of Exelixis worth $4,610,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in EXEL. CWM LLC boosted its stake in shares of Exelixis by 17.3% during the 3rd quarter. CWM LLC now owns 7,698 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 1,136 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Exelixis during the 3rd quarter worth about $1,742,000. Ballentine Partners LLC bought a new stake in shares of Exelixis during the 3rd quarter worth about $301,000. Denali Advisors LLC boosted its stake in shares of Exelixis by 7,995.2% during the 3rd quarter. Denali Advisors LLC now owns 1,700 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,679 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Exelixis by 4.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 120,479 shares of the biotechnology company’s stock worth $2,632,000 after acquiring an additional 4,639 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In related news, Director David Edward Johnson bought 190,000 shares of the company’s stock in a transaction dated Wednesday, February 21st. The stock was acquired at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the acquisition, the director now owns 1,100,730 shares in the company, valued at approximately $22,785,111. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director David Edward Johnson bought 190,000 shares of the company’s stock in a transaction dated Wednesday, February 21st. The stock was acquired at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the acquisition, the director now owns 1,100,730 shares in the company, valued at approximately $22,785,111. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Patrick J. Haley sold 47,020 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now directly owns 384,866 shares of the company’s stock, valued at $8,255,375.70. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EXEL. JMP Securities reiterated a “market outperform” rating and set a $27.00 price target on shares of Exelixis in a research note on Wednesday, April 10th. William Blair restated an “outperform” rating on shares of Exelixis in a research note on Friday, January 26th. Stifel Nicolaus increased their target price on Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, March 18th. Finally, Royal Bank of Canada increased their target price on Exelixis from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.29.

Exelixis Stock Up 0.7 %

Exelixis stock opened at $23.70 on Friday. Exelixis, Inc. has a 12 month low of $18.08 and a 12 month high of $24.34. The business has a 50 day moving average price of $22.80 and a two-hundred day moving average price of $22.18. The stock has a market cap of $6.99 billion, a price-to-earnings ratio of 37.03, a price-to-earnings-growth ratio of 0.63 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. The business had revenue of $479.65 million during the quarter, compared to analysts’ expectations of $481.23 million. On average, analysts expect that Exelixis, Inc. will post 1.21 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.